Skip to Content
MilliporeSigma
  • Free thyroxine levels after very preterm birth and neurodevelopmental outcomes at age 7 years.

Free thyroxine levels after very preterm birth and neurodevelopmental outcomes at age 7 years.

Pediatrics (2014-04-02)
Shannon E Scratch, Rodney W Hunt, Deanne K Thompson, Zohra M Ahmadzai, Lex W Doyle, Terrie E Inder, Peter J Anderson
ABSTRACT

Preterm infants commonly have transient hypothyroxinemia of prematurity after birth, which has been associated with deficits in general intellectual functioning, memory, attention, and academic achievement. However, research has predominantly focused on thyroxine levels in the first 2 weeks of life and outcomes are limited to the preschool period. Our objective was to evaluate the relationships between free thyroxine (fT₄) levels over the first 6 weeks after very preterm (VPT) birth with cognitive functioning and brain development at age 7 years. A total of 83 infants born VPT (<30 weeks' gestation) had fT₄ concentrations measured postnatally and 2- and 6-week area under the curve (AUC) summary measures were calculated. Follow-up at age 7 years included a neuropsychological assessment and brain MRI. Univariable and multivariable regression modeling was used where AUC for fT₄ was the main predictor of neurodevelopmental outcome at age 7 years. Multivariable modeling revealed that higher, not lower, postnatal fT₄ levels (2-week AUC) were associated with poorer cognitive performances at age 7 years on tasks of verbal learning (P = .02), verbal memory (P = .03), and simple reaction time (P < .001). A similar pattern of results was found when the 6-week AUC was examined. No significant associations between postnatal fT₄ levels and brain volumes at age 7 years were identified. Results are contradictory to previous observations and suggest that after adjustment for confounders, higher postnatal fT₄ levels in VPT infants, rather than lower levels, may be a marker of adverse neuropsychological development in childhood.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
L-Thyroxine, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
L-Thyroxine, ≥98% (HPLC)
Supelco
L-Thyroxine (T4) solution, 100 μg/mL in methanol with 0.1N NH3, ampule of 1 mL, certified reference material, Cerilliant®
USP
Levothyroxine, United States Pharmacopeia (USP) Reference Standard